Illumina, Inc.  

(Public, NASDAQ:ILMN)   Watch this stock  
Find more results for ILMN
243.55
+2.24 (0.93%)
Jan 19 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 241.44 - 244.88
52 week 156.50 - 248.97
Open 242.31
Vol / Avg. 896,733.00/872,884.00
Mkt cap 35.56B
P/E 45.91
Div/yield     -
EPS 5.30
Shares 146.00M
Beta 0.79
Inst. own 94%
Jan 30, 2018
Q4 2017 Illumina Inc Earnings Call - 5:00PM EST - Add to calendar
Jan 30, 2018
Q4 2017 Illumina Inc Earnings Release - 4:00PM EST - Add to calendar
Jan 8, 2018
Illumina Inc at JPMorgan Healthcare Conference - Question & Answer Session
Jan 8, 2018
Illumina Inc at JPMorgan Healthcare Conference - Webcast
Dec 7, 2017
Illumina Inc at Citi Global Healthcare Conference - Webcast
Nov 30, 2017
Illumina Inc at Deutsche Bank MedTools and Diagnostics One-on-One Day
Oct 24, 2017
Q3 2017 Illumina Inc Earnings Call - Webcast
Oct 24, 2017
Q3 2017 Illumina Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Oct '17) 2017
Net profit margin 21.29% 17.85%
Operating margin 25.35% 24.48%
EBITD margin - 30.02%
Return on average assets 12.31% 10.74%
Return on average equity 23.48% 22.87%
Employees 5,500 -
CDP Score - -

Address

5200 Illumina Way
SAN DIEGO, CA 92122-4616
United States - Map
+1-858-2024500 (Phone)
+1-858-2024766 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina's products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. The Company's portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing.

Officers and directors

Jay T. Flatley Executive Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Francis A. deSouza President, Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Sam Samad Chief Financial Officer, Senior Vice President
Age: 47
Bio & Compensation  - Reuters
Marc A. Stapley Executive Vice President, Chief Administrative Officer
Age: 46
Bio & Compensation  - Reuters
Garret Hampton Ph.D. Executive Vice President - Clinical Genomics
Age: 51
Bio & Compensation  - Reuters
Omead Ostadan Executive Vice President - Operations, Products and Strategy
Age: 45
Bio & Compensation  - Reuters
Mostafa Ronaghi Ph.D. Chief Technology Officer, Senior Vice President
Age: 47
Bio & Compensation  - Reuters
Charles E. Dadswell Senior Vice President, General Counsel, Secretary
Age: 57
Bio & Compensation  - Reuters
Aimee Hoyt Senior Vice President and Chief People Officer
Bio & Compensation  - Reuters
Mark Van Oene Senior Vice President, Chief Commercial Officer
Bio & Compensation  - Reuters